Eleven research firms presently covering Encompass Health have delivered an average recommendation of “Buy,” according to MarketBeat Ratings. Of those, two analysts have assigned a strong buy rating, eight have issued a buy rating and one has adopted a hold position. Over the past quarter, Raymond James Financial elevated its view to strong buy, Barclays maintained an overweight stance, KeyCorp reaffirmed its overweight rating, Wall Street Zen shifted from buy to hold and Weiss Ratings restated a buy (B+) assessment, underscoring broad confidence in the company’s recovery‐care model.

Encompass Health will report results for the quarter ended December 31, 2025, after market close on Thursday, February 5, 2026. Management will host a conference call at 10:00 a.m. ET on Friday, February 6 to discuss fourth quarter financials, strategic initiatives and guidance for 2026. Investors may access the call via domestic and international dial‐in numbers or through a webcast replay later on the company’s investor relations website.

In the quarter ended March 31, Encompass Health delivered revenue of $136.3 million, generating net margin of 9.33% and return on equity of 17.84%. The company’s balance sheet reflects a debt‐to‐equity ratio of 0.76, a current ratio of 1.14 and a quick ratio of 1.14, indicating liquidity strength. Analysts forecast full‐year earnings per share of approximately 4.8, while the dividend payout ratio stands at 14.37%, translating to an annualized yield of 0.7%.

Encompass Health operates a nationwide network of 173 inpatient rehabilitation hospitals across 39 U.S. states and Puerto Rico, supplemented by home health and hospice services. The company’s inpatient facilities provide intensive therapy for stroke, brain and spinal cord injuries, cardiac and pulmonary disorders, and orthopedic recovery, while home segments deliver skilled nursing and rehabilitation in patient residences. Institutional investors hold 97.25% of outstanding shares, with recent small‐cap fund purchases highlighting continued confidence from diversified asset managers.